Skip to main content
SOLV logo

SOLV · Solventum Corp

Track SOLV — free
$87.40 -1.25 (-1.41%)
Market Cap
$15.05B
Shares
169.74M
Volume · Nov 17 59.83K Avg daily vol (3M) 1.05M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$88.65 Open$88.56 Day$88.56–89.83 52W close$62.49–92.44 Avg vol 30d1.2M Short int5.0M · 3.0% of shares · 4.6d Short vol47% Last earningsNov 5, 2026 DataMar 2024–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Earnings call
2026 EPS outlook raised as separation nears completion

Solventum raised its 2026 EPS outlook to $7.20 to $7.30, reported normalized organic growth of approximately 4%, expects full-year gross margin of approximately 57%, and says separation from 3M is more than 90% complete.

5 source passages
Given our performance through the first nine months of the year and expectations for the remainder of 2026, we now expect earnings per share of $7.20 to $7.30. Compared with our prior range of $7.10 to $7.20. Q3 organic growth on a normalized basis was approximately 4% when taking into consideration the ERP-related timing impact and 90 basis points of SKU rationalization headwinds. Following the stronger-than-expected gross margins in Q3, We now expect our full-year gross margins will be approximately 57%, which includes 120 basis points annual margin benefit from the Q2 tariff refund, which offsets the expected full-year tariff cost. We are now more than 90% through our separation from 3M, with the heaviest lift complete. This is a significant milestone for Solventum, and I'm extremely proud of the team for getting us here. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter sales fell 7.0%; operating income dropped 96.0%

Solventum reported third-quarter sales of $1,949 million, down 7.0%, and operating income of $68 million, down 96.0%, as the prior-year divestiture gain fell away and ERP order timing weighed on sales.

Revenue $1.95B ▼ 7.0% Net loss $12M Diluted EPS -$0.07
Read from the MD&A section
4 source passages
Solventum manages its operations in three reportable business segments: MedSurg, Dental Solutions, and Health Information Systems. Total Company | 1,949 | 2,096 | (7.0)% Total Company | 68 | 1,690 | (96.0)% The Company’s sales in the third quarter of 2026 were negatively impacted as customers reduced inventory to normal levels following a second quarter 2026 benefit of approximately $125 million from advanced customer ordering in connection with the Company's July 2026 U.S. enterprise resource planning ("ERP") deployment. Open the document at this passage
Nov 5
Current report 8-K
Adjusted EPS guidance raised despite quarterly sales decline

Solventum reported third-quarter sales of $1.9 billion, down 7.0%, and adjusted diluted EPS of $1.45, while raising full-year adjusted EPS guidance to $7.20 to $7.30 and expecting organic sales growth toward the high end of +2.5% to +3.0%.

Financial results
5 source passages
EAGAN, Minn., November 5, 2026 – Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2026. •Sales of $1.9 billion, decreased 7.0% on a reported basis; a decrease of 2.8% on an organic basis •GAAP diluted earnings per share of $(0.07); adjusted diluted earnings per share of $1.45, a 3.6% decrease •Expects full-year organic sales growth toward the high end of +2.5% to +3.0% range •Increases full-year adjusted EPS guidance to $7.20 to $7.30 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.16B
Trailing 12 months
Net income (TTM)
$156.00M
Trailing 12 months
Revenue growth YoY
-7.0%
Year over year
Operating margin
5.6%
Trailing 12 months
P / E (TTM)
99.0
Trailing earnings · reciprocal yield 1.0%
FCF yield
0.0%
TTM · current market cap
Return on invested capital
4.4%
Trailing 12 months
Net cash
−$4.62B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.6%
Year over year · fewer shares
Price change (1Y)
+18.4%
Trailing year
Short interest
3.0%
Latest settlement · 4.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Solventum raised adjusted EPS guidance, moved organic sales and operating-margin guidance toward the high ends of their ranges, expanded gross margin and achieved approximately 4% normalized organic growth, and reported growth from Acera and favorable regulatory clearance. It also nearly completed the 3M separation, generated $97 million of quarterly free cash flow, maintained $200 to $300 million free-cash-flow guidance, and benefited from a renegotiated 3M supply agreement. Third-quarter reported and organic sales, adjusted operating margin and adjusted EPS declined, while the planned HIS separation is expected to dilute annualized net operating margin by approximately 400 basis points.

Bullish
  • + Full-year adjusted EPS guidance increased to $7.20 to $7.30 from $7.10 to $7.20.
  • + Full-year organic sales growth guidance moved toward the high end of 2.5% to 3.0%.
  • + Full-year operating-margin guidance moved toward the high end of 22.2% to 22.7%, while full-year gross margin is expected to be approximately 57%.
Bearish
  • − Third-quarter reported sales declined 7.0% and organic sales declined 2.8%.
  • − Adjusted operating margin declined 70 basis points year over year to 19.9%.
  • − Adjusted diluted earnings per share declined 3.6% to $1.45.
  • − The ERP-related advance-order reversal reduced organic sales growth by 630 basis points in the quarter.
  • − The planned HIS separation is expected to dilute annualized net operating margin by approximately 400 basis points.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +1%
above
RSI (14) 54
neutral
MACD trend Positive
52-week position 87%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +4%
trailing
6-month return +17%
trailing
YTD return +12%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $87 › 200d $79 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +90 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.97% of shares out · ▲ +1.9% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
891 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Fair
Revenue growth +1%
Y/Y
Gross margin 53%
contracting
EPS growth +222%
Y/Y
Free cash flow $-10.0M
Valuation P/E 98.5
rich
Buyback $1.0B
authorized
Balance sheet $4.2B
net debt
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −27%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 5, 2026
Organic sales growth · full year 2026 Non-GAAP 2.5% – 3%
Adjusted EPS · full year 2026 Non-GAAP Raised $7.20 – $7.30
Aug 5, 2026 $7.10 – $7.20 changed to Nov 5, 2026 $7.20 – $7.30
Free cash flow · full year 2026 Non-GAAP Maintained $200M – $300M
Aug 5, 2026 $200M – $300M changed to Nov 5, 2026 $200M – $300M
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Earnings per share · full year 2026 $7.10 – $7.20
Non-operating expense · full year 2026 $300M
Operating margin · full year 2026 22.2% – 22.7%
Non-operating expenses · full year 2026 $300M
Tax rate · full year 2026 19.5% – 20.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
54 Neutral
MACD trend
Positive Bullish
52-week position
87% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $87 › 200d $79 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +90 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.97% of shares out · ▲ +1.9% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
891 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $62 Now $89 · 87% Range high $92
vs 200-day avg +12% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted operating income margin non-GAAP 24.2% Six months ended June 30, 2026 —
Free cash flow non-GAAP -$129M Six months ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities 227M
-83M Purchases of property, plant and equipment
= Free cash flow 144M
Organic sales growth non-GAAP 5.8% Six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SOLV
Solventum Corp
this stock
$15.05B +11.9% +0.9% 98.5 3.0%
ISRG
Intuitive Surgical Inc
$150.74B -22.7% +20.5% 53.1 2.0%
BDX
Becton Dickinson & Co
$58.96B — +8.2% 95.8 3.0%
MDLN
Medline Inc.
$51.52B -6.7% +11.5% — 2.9%
ALC
Alcon Inc
$35.38B -6.6% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
891
% held
74.9%
Net QoQ
-408.4K sh
Top holder
Independent Franchise Par…
Held Float
View
Held by Funds
Fund positions
513
View
Short & Settlement
Short Interest Rising
Shares short
5.0M
Days to cover
4.6d
Change
+95.7K sh
View
Short Volume
Short vol %
47%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
40
Value
$3.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
42.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$8.3B
Net income (FY)
$1.6B
EPS diluted
$8.88
View
Buybacks
Authorized
$1.0B
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
18

Solventum reported third-quarter sales of $1,949 million, down 7.0%, and operating income of $68 million, down 96.0%, as the prior-year divestiture gain fell away and ERP order timing weighed on sales.

View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Solventum Reports Third Quarter 2…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
SOLV -2.0% +4.2% +16.8% +9.0% +11.9%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -0.3% +7.7% +18.2% +11.1% +3.4%

Capital returns

Buyback program · as of Dec 16, 2025
Authorized
$1.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1964738 CUSIP 83444M101 13F (30d) 850 filings 794 filers Visit website Investor relations